Delivering Rapid Relief When Every Second Counts
Nasus Pharma Ltd. (NYSE American: NSRX) is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, utilizing its proprietary powder-based intranasal (PBI) platform to address acute medical conditions and public health threats.
LATEST NEWS
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Identifying The Opportunity
KEY LEVELS
Key Level #1 - $3.14
Key Level #2 - $3.48
Key Level #3 - $4.07
Support: $2.62
About Nasus Pharma Ltd.
Nasus Pharma Ltd. (NYSE American: NSRX) is a clinical-stage pharmaceutical company incorporated in 2019 and based in Tel Aviv-Yafo, Israel. The company is focused on the development of innovative intranasal products utilizing its proprietary powder-based intranasal (PBI) platform to address acute medical conditions and public health threats. Nasus Pharma's mission is to offer better protection to patients during severe, life-threatening conditions through effective, user-friendly, safe, and immediately active intranasal products, with a focus on rapid drug delivery, ease of use, non-invasiveness, and safety. The company completed its NYSE American IPO in August 2025 and its ordinary shares trade under the ticker symbol NSRX.
Nasus Pharma Ltd.
Proprietary PBI Platform Technology
- Nasus Pharma's powder-based intranasal (PBI) platform disperses drug particles broadly across the nasal cavity, creating a larger absorption area than liquid-based nasal solutions, enabling rapid and high drug absorption.
- Uniform spherical powder particles enhance dose consistency and reliability, leveraging the nasal cavity's rich vascular network for near-immediate systemic delivery.
- The platform has been validated in clinical studies with NS002 (epinephrine) and in preclinical or in-vitro settings with NS001 (naloxone), midazolam, and atropine.
- The PBI platform supports a growing pipeline across acute and life-threatening conditions:
- NS002→ intranasal epinephrine for anaphylaxis (Phase 2 complete)
- NS003→ intranasal ondansetron for chemotherapy-induced nausea
- Earlier-stage assets includeNS004, targeting metabolic disorders, and NS005 for cardiovascular diseases
Operational Momentum and Scaling
- NS002 is advancing toward a pivotal Phase 3 study, with an IND submission planned for Q3 2026 and Phase 3 initiation targeted for Q4 2026, following statistically significant Phase 2 results demonstrating superiority to EpiPen on time to therapeutic threshold.
- In November 2025, Nasus launched an additional Phase 2 study in Canada evaluating NS002's pharmacokinetic parameters and hemodynamic responses vs. EpiPen in 50 healthy adults with a history of allergic rhinitis, further building the clinical package ahead of regulatory submission under Section 505(b)(2).
- NS003 (intranasal ondansetron) and NS004 (metabolic disorders) are advancing toward first-in-human Phase 1 studies expected in H2 2026, while NS001 (intranasal naloxone) development is paused as the company pursues partnering opportunities for its further advancement.
Positioning for Long-Term Value Creation
- Nasus Pharma is building a diversified intranasal drug delivery business around its proprietary PBI platform, targeting high-urgency, life-threatening conditions where rapid, non-invasive administration offers a meaningful clinical advantage.
- With NS002 addressing the large and established epinephrine autoinjector market and earlier-stage assets in oncology support and metabolic disease, the company offers a portfolio approach to value creation across multiple indication areas.
- The February 2026 $15 million private placement extended the cash runway through mid-2027, providing the capital needed to advance NS002 through Phase 3 initiation while progressing NS003 and NS004 into first-in-human studies.
Financials
Nasus Pharma reported a net loss of $5.9 million for fiscal year 2025, with R&D and G&A expenses reflecting the company's transition to public company status and acceleration of the NS002 program.
Key Financial Highlights (FY2025):
• Cash, Cash Equivalents and Marketable Securities: $4.3M (December 31, 2025)
• Post-Period Private Placement (February 2026): $15.0M gross proceeds
• FY2025 Net Loss: $(5.9M) (vs. $(1.5M) in FY2024)
• R&D Expenses: $2.4M (FY2025, up from $0.3M in FY2024)
• G&A Expenses: $2.7M (FY2025, up from $0.7M in FY2024)
• Accumulated Deficit: approximately $18.5M as of December 31, 2025
Introducing the Leadership Team of Nasus Pharma Ltd. (NYSE American: NSRX)
Dan Teleman, MBA, M.Sc.
Chief Executive Officer
Dan Teleman, MBA, M.Sc., has served as Chief Executive Officer of Nasus Pharma since January 2025 and as a Director since September 2025. He leads the company's strategic direction, clinical development programs, and capital markets activities as Nasus advances its lead asset NS002 toward a pivotal Phase 3 study.
Eyal Rubin
Executive Vice President and Chief Financial Officer
Eyal Rubin was appointed Executive Vice President and Chief Financial Officer of Nasus Pharma, effective November 20, 2025, bringing more than two decades of financial leadership experience in global biotechnology and pharmaceutical industries. He previously served as CFO and Senior Vice President of Protalix BioTherapeutics, CFO of BrainStorm Cell Therapeutics, and Vice President and Head of Corporate Treasury at Teva Pharmaceutical Industries. Mr. Rubin holds a BA in Business Management and an MBA in Accounting and Finance from Bar-Ilan University, both summa cum laude.
Dr. Dalia Megiddo
Co-Founder, Board Member, and Chief Development Officer
Dr. Dalia Megiddo serves as Co-Founder, Board Member, and Chief Development Officer of Nasus Pharma. She is one of the founding members of the company and has played a central role in the development of the proprietary PBI platform technology and the advancement of the clinical pipeline, including overseeing the NS002 intranasal epinephrine program and the broader product portfolio across acute medical conditions. The company's additional leadership team includes Tair Lapidot, PhD (VP of Research and Development and Clinical Development), Carolina Abrutzky (VP of CMC), Galia Temtsin Krayz, PhD (Director of Product Development), and Yifat Bar (VP of Administration and Human Resources).
We get our information from SEC filings and verified public sources.
Stay Ahead. Stay Informed. Stay Profitable.
Subscribe to See What They're Watching
Sources
Home
https://www.sec.gov/ (NSRX SEC Filings, Form 20-F)
https://www.globenewswire.com/ (Press Releases)
https://www.biospace.com/ (News Coverage)
https://www.tradingview.com/symbols/AMEX-NSRX/
Disclaimer
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Pursuant to an agreement between JRZ Capital and Virtus Media Group LLC, Virtus Media has been hired to publicly disseminate information about ticker $NSRX via digital communications beginning May 28th, 2026 ending June 1st, 2026. Virtus will be paid $25,000 from JRZ Capital.
